NightstaRX raises $35m series B

Founding investor Syncona, a subsidiary of the Wellcome Trust, also contributed to the round.

Company
NightstaRX's lead programme is a gene therapy for an inherited form of progressive blindness - choroideremia - developed by professor Robert MacLaren at Oxford's Nuffield Laboratory of Ophthalmology. Choroideremia affects around one in 50,000 people.

NightstaRX spun out of Oxford University in 2014 and is focused on the development of therapies for retinal dystrophies.

People
As part of the investment, David Mott, general partner at NEA, has joined the board of NightstaRX. Chris Hollywood, a partner at Syncona, is chair of NightstaRX.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Expansion
• Healthcare
• United Kingdom